1. Home
  2. TGL vs BCAB Comparison

TGL vs BCAB Comparison

Compare TGL & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TGL

Treasure Global Inc.

HOLD

Current Price

$3.85

Market Cap

7.2M

Sector

Technology

ML Signal

HOLD

Logo BioAtla Inc.

BCAB

BioAtla Inc.

HOLD

Current Price

$4.19

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TGL
BCAB
Founded
2020
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2M
6.4M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
TGL
BCAB
Price
$3.85
$4.19
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
46.3K
50.9K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.86
EPS
N/A
N/A
Revenue
$2,330,557.00
$300,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$0.12
52 Week High
$58.00
$6.52

Technical Indicators

Market Signals
Indicator
TGL
BCAB
Relative Strength Index (RSI) 47.57 59.54
Support Level $3.92 $3.92
Resistance Level $4.30 $4.22
Average True Range (ATR) 0.29 0.39
MACD -0.02 0.08
Stochastic Oscillator 36.54 86.31

Price Performance

Historical Comparison
TGL
BCAB

About TGL Treasure Global Inc.

Treasure Global Inc has created an online-to-offline e-commerce platform business model that offers consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retail or merchant settings. Its product is an internet application branded as the ZCITY app, which targets consumers by providing personalized deals based on their purchase history, location, and preferences. The Company has two reportable segments: payment processing and e-commerce operation in its ZCITY platform, and customized software development service, and the majority of revenue comes from payment processing and e-commerce operation in its ZCITY platform.

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.

Share on Social Networks: